专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100105772A1 USE OF NOVEL LIPID MEDIATORS TO INHIBIT ANGIOGENESIS 审中-公开
标题翻译：使用新型脂质介质抑制血管生成
公开(公告)号：US20100105772A1
公开(公告)日：2010-04-29
申请号：US12430287
申请日：2009-04-27
申请人： Charles N. Serhan , Reza Dana , Yiping Jin
发明人： Charles N. Serhan , Reza Dana , Yiping Jin
IPC分类号： A61K31/235 , A61K31/202
CPC分类号： A61K31/202 , A61K31/235
摘要： The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (PUFA) such as arachidonic acid (AA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of AA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of AA (lipoxins, aspirin-triggered epi-lipoxins) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
摘要翻译：通常，本发明涉及由膳食ω-6多不饱和脂肪酸（PUFA）如花生四烯酸（AA），加氧酶和止痛阿司匹林（ASA）之间的相互作用产生的新型分离的治疗剂，称为脂氧素。令人惊讶的是，在合适的环境中仔细分离由组分组合产生的化合物，提供具有独特结构和生理特性的含AA化合物的二羟基和三羟基衍生物。因此，本发明提供了减少，预防或消除角膜组织的NV，血管生成和/或血管生成状态的许多新的有用的治疗性二羟基和三羟基衍生物（脂氧素，阿司匹林触发的表皮脂氧素）。本发明还提供了用于本说明书中公开的化合物的药物用途，制备方法和包装药物的方法。

2. 发明申请

US20140094519A1 LIPOXIN ANALOGS AS NOVEL INHIBITORS OF ANGIOGENESIS 有权
标题翻译： LIPOXIN类似物作为血管生成的新型抑制剂
公开(公告)号：US20140094519A1
公开(公告)日：2014-04-03
申请号：US13106450
申请日：2011-05-12
申请人： Charles N. Serhan , Reza Dana , Yiping Jin
发明人： Charles N. Serhan , Reza Dana , Yiping Jin
IPC分类号： C07C57/03 , C07C57/42
CPC分类号： C07C57/03 , A61K31/202 , C07C57/42
摘要： The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (PUFA) such as arachidonic acid (AA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of AA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of AA (lipoxins, aspirin-triggered epi-lipoxins) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
摘要翻译：通常，本发明涉及由膳食ω-6多不饱和脂肪酸（PUFA）如花生四烯酸（AA），加氧酶和止痛阿司匹林（ASA）之间的相互作用产生的新型分离的治疗剂，称为脂氧素。令人惊讶的是，在合适的环境中仔细分离由组分组合产生的化合物，提供具有独特结构和生理特性的含AA化合物的二羟基和三羟基衍生物。因此，本发明提供了减少，预防或消除角膜组织的NV，血管生成和/或血管生成状态的许多新的有用的治疗性二羟基和三羟基衍生物（脂氧素，阿司匹林触发的表皮脂氧素）。本发明还提供了用于本说明书中公开的化合物的药物用途，制备方法和包装药物的方法。

3. 发明授权

US08722654B2 Lipoxin analogs as novel inhibitors of angiogenesis 有权
标题翻译：脂氧素类似物作为血管发生的新型抑制剂
公开(公告)号：US08722654B2
公开(公告)日：2014-05-13
申请号：US13106450
申请日：2011-05-12
申请人： Charles N. Serhan , Reza Dana , Yiping Jin
发明人： Charles N. Serhan , Reza Dana , Yiping Jin
IPC分类号： A01N43/00 , A61K31/33
CPC分类号： C07C57/03 , A61K31/202 , C07C57/42
摘要： The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (PUFA) such as arachidonic acid (AA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of AA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of AA (lipoxins, aspirin-triggered epi-lipoxins) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
摘要翻译：通常，本发明涉及由膳食ω-6多不饱和脂肪酸（PUFA）如花生四烯酸（AA），加氧酶和止痛阿司匹林（ASA）之间的相互作用产生的新型分离的治疗剂，称为脂氧素。令人惊讶的是，在合适的环境中仔细分离由组分组合产生的化合物，提供具有独特结构和生理特性的含AA化合物的二羟基和三羟基衍生物。因此，本发明提供了减少，预防或消除角膜组织的NV，血管生成和/或血管生成状态的许多新的有用的治疗性二羟基和三羟基衍生物（脂氧素，阿司匹林触发的表皮脂氧素）。本发明还提供了用于本说明书中公开的化合物的药物用途，制备方法和包装药物的方法。

4. 发明申请

US20110301239A1 USE OF NOVEL LIPID MEDIATORS TO INHIBIT ANGIOGENESIS 审中-公开
标题翻译：使用新型脂质介质抑制血管生成
公开(公告)号：US20110301239A1
公开(公告)日：2011-12-08
申请号：US12989626
申请日：2009-04-27
申请人： Charles N. Serhan , Reza Dana , Yiping Jin
发明人： Charles N. Serhan , Reza Dana , Yiping Jin
IPC分类号： A61K31/201 , A61P27/02 , A61P9/00
CPC分类号： A61K31/047 , A61K31/202
摘要： The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of EPA or DHA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of EPA or DHA (resolvins of the E series and D series) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
摘要翻译：通常，本发明涉及由膳食ω-3多不饱和脂肪酸（PUFA）如二十碳五烯酸（EPA）或二十二碳六烯酸（DHA）加氧酶与镇痛阿司匹林之间的相互作用产生的新型分离的治疗剂，称为溶血素，作为一个）。令人惊奇的是，在合适的环境中仔细分离由组分组合产生的化合物，提供具有独特结构和生理特性的含有EPA或DHA的化合物的二羟基和三羟基衍生物。因此，本发明提供了EPA或DHA（E系列和D系列的溶血素）的许多新的有用的治疗性二 - 和三羟基衍生物，其减少，预防或消除NV，血管发生和/或血管生成状态角膜组织本发明还提供了用于本说明书中公开的化合物的药物用途，制备方法和包装药物的方法。

5. 发明授权

US07662552B2 Method of diagnosing and treating lesion of crystalline lens using human CRYGS gene and coding product thereof 有权
标题翻译：使用人CRYGS基因诊断和治疗晶状体损伤的方法及其编码产物
公开(公告)号：US07662552B2
公开(公告)日：2010-02-16
申请号：US10362817
申请日：2001-08-24
申请人： Xiangyin Kong , Lei Bu , Guoping Zhao , Shunsheng Yan , Meilei Jin , Yerjiang Sulitang , Yiping Jin , Liandian Hu
发明人： Xiangyin Kong , Lei Bu , Guoping Zhao , Shunsheng Yan , Meilei Jin , Yerjiang Sulitang , Yiping Jin , Liandian Hu
IPC分类号： C12Q1/68 , C12P19/34 , C07H21/02
CPC分类号： C07K14/47 , A61K38/00
摘要： The method of diagnosing lesions of crystalline lens such as cataract is disclosed. It comprises detecting variation of crygs gene, transcript and/or protein of individuals compared with normalty. The individual suffers from cataract more possible than normalty when occurring the variation. The present invention also discloses the method and pharmaceutical composition of treating lesions of crystalline lens such as cataract.
摘要翻译：公开了诊断白内障晶状体病变的方法。它包括检测与正常人相比，crygs基因，转录物和/或蛋白质的变化。发生变异时，个体患白内障的可能性比正常人多。本发明还公开了治疗诸如白内障的晶状体损伤的方法和药物组合物。

6. 发明申请

US20070259428A1 Use of Cloud Point System in Biotransformation 审中-公开
标题翻译：使用云点系统进行生物转化
公开(公告)号：US20070259428A1
公开(公告)日：2007-11-08
申请号：US10567439
申请日：2004-07-05
申请人： Daijie Chen , Zhilong Wang , Mei Ge , Yiping Jin , Weidong Ye
发明人： Daijie Chen , Zhilong Wang , Mei Ge , Yiping Jin , Weidong Ye
IPC分类号： C12N15/87
CPC分类号： C12P33/02 , C12N1/38
摘要： The invention relates to the field of microbial technology. It discloses a method to apply the cloud point system (CPS) in biotransformation by selecting one or more types of nonionic surfactant to form a aqueous system with a cloud point below the microbial transformation temperature, which serves as transformation medium. The method disclosed is suitable in particular for microbial transformation of hydrophobic compounds, for the system where substrate or product inhibits microbial growth or where product is further degraded by microbes. The CPS in the present invention forms a microemulsion of water-in-oil and oil-in-water, where the drops of surfactant is able to solubilize, serving as substrate reservoir and product extractant. This enhances bioavailability of substrates and elimination of product inhibition. The large water vesicles existing in the continuous surfactant phase provide aqueous environment to the cells where they can be sheltered from detrimental effects of surfactants, resulting in improvement of biocompatibililty.
摘要翻译：本发明涉及微生物技术领域。它公开了一种通过选择一种或多种类型的非离子表面活性剂来应用浊点系统（CPS）进行生物转化的方法，以形成低于微生物转化温度的浊点的水系，其作为转化介质。所公开的方法特别适用于疏水化合物的微生物转化，其中底物或产物抑制微生物生长或其中产物被微生物进一步降解的系统。本发明中的CPS形成了油包水和水包油的微乳液，其中表面活性剂的液滴能够溶解，作为底物贮存器和产物萃取剂。这增强了底物的生物利用度和消除了产物的抑制作用。存在于连续表面活性剂相中的大水泡为细胞提供水环境，在那里可以避免表面活性剂的不利影响，导致生物相容性的提高。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式